Home
About
About The Guide to MALARIA PHARMACOLOGY
The Guide to PHARMACOLOGY
About The Guide to PHARMACOLOGY
About NC-IUPHAR
Contributors
Sponsors
Citing
Linking to us
Disclaimer
Privacy and Cookie Policy
Targets
Antimalarial targets
Ligands
Ligand list
Ligand families
Ligand search
Lifecycle
Plasmodium liver stage
Plasmodium dormant liver stage
Plasmodium asexual blood stage
Plasmodium sexual blood stage
Plasmodium mosquito host
Species
P. falciparum
P. vivax
P. knowlesi
P. berghei
P. cynomolgi
P. yoelii
Resources
GtoMPdb Help
GtoPdb Help
FAQ
Terms and symbols
Nomenclature guidelines
Publications
Concise Guide to PHARMACOLOGY
Useful links
GtoPdb Downloads
Download data and reports
Web services
Slides and posters
GtoPdb News
Immunopharmacology Meeting 2018
Latest GtoPdb news
Hot topics
Guide to PHARMACOLOGY
Home
About
Help
Home
Ligands
mosunetuzumab
mosunetuzumab
GtoPdb Ligand ID: 12298
Synonyms:
BTCT4465A | CD20-TDB [
7
] | Lunsumio® | mosunetuzumab-axgb | RG-7828 | RO7030816
mosunetuzumab is an
approved drug
(EMA & FDA (2022))
Compound class:
Antibody
Comment:
Mosunetuzumab (BTCT4465A) is an anti-CD20(
MS4A1
)/CD3e bispecific antibody [
7
] that was developed by Roche/Genentech to eliminate CD20+ve B cell malignancies by recruiting and activating effector T cells [
1
,
4-5
].
Summary
Biological activity
Clinical data
References
Bioactivity Comments
Mosunetuzumab effectively kills patient-derived CLL B cells
in vitro
and
in vivo
[
7
].
Selectivity at other protein targets
Key to terms and symbols
Click column headers to sort
Target
Sp.
Type
Action
Value
Parameter
Concentration range (M)
Reference
CD20 (membrane-spanning 4-domains, subfamily A, member 1)
Hs
Antibody
Binding
-
-
-
7
⤷
[
7
]
CD3e
Hs
Antibody
Agonist
-
-
-
7
⤷
[
7
]